United States · Platforms & data · TipRanks

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Published by TipRanks · United States 10 h ago

Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, ...

Read the full article on TipRanks Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tipranks.com)

Also worth reading

MarketBeat

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

The Motley Fool

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

TheStreet

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Share

Also worth reading

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Down 17%, Is Meta a Buy on the Dip?

Johnson & Johnson reports response rate for head, neck cancer treatment

Goldman lists 3 factors that support long commodities positions

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120